CD8A and neoplasm: To further investigate the effect of transferred vs. endogenous OVA-specific CD8+ T cells on antitumor efficacy, we employed OVA tetramer+ CD8+ T cells from CD45.2 expressing donors (OT-I mice) and transferred them to CD45.1 expressing tumor bearing mice (Fig. 7c).